vs
化石集团（FOSL）与PHIBRO ANIMAL HEALTH CORP（PAHC）财务数据对比。点击上方公司名可切换其他公司
PHIBRO ANIMAL HEALTH CORP的季度营收约是化石集团的1.4倍（$373.9M vs $270.2M），PHIBRO ANIMAL HEALTH CORP净利率更高（7.3% vs -14.8%，领先22.2%），PHIBRO ANIMAL HEALTH CORP同比增速更快（20.9% vs -21.1%），PHIBRO ANIMAL HEALTH CORP自由现金流更多（$8.3M vs $-22.5M），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs -11.4%）
化石集团是1984年成立的美国时尚设计制造企业，总部位于得克萨斯州理查森。集团旗下拥有Fossil、Relic、Michele Watch、Skagen、Zodiac Watches等多个品牌，同时也为宝马、彪马、阿玛尼、迈克高仕、DKNY等多个知名品牌代工生产授权配饰。
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
FOSL vs PAHC — 直观对比
营收规模更大
PAHC
是对方的1.4倍
$270.2M
营收增速更快
PAHC
高出42.0%
-21.1%
净利率更高
PAHC
高出22.2%
-14.8%
自由现金流更多
PAHC
多$30.8M
$-22.5M
两年增速更快
PAHC
近两年复合增速
-11.4%
损益表 — Q3 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $270.2M | $373.9M |
| 净利润 | $-40.0M | $27.5M |
| 毛利率 | 49.0% | 35.5% |
| 营业利润率 | -8.0% | 13.5% |
| 净利率 | -14.8% | 7.3% |
| 营收同比 | -21.1% | 20.9% |
| 净利润同比 | -257.8% | 762.1% |
| 每股收益（稀释后） | $-0.76 | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FOSLPAHC
| Q4 25 | $270.2M | $373.9M | ||
| Q3 25 | $220.4M | $363.9M | ||
| Q2 25 | $233.3M | $378.7M | ||
| Q1 25 | — | $347.8M | ||
| Q4 24 | $342.3M | $309.3M | ||
| Q3 24 | $287.8M | $260.4M | ||
| Q2 24 | $260.0M | $273.2M | ||
| Q1 24 | $254.9M | $263.2M |
净利润FOSLPAHC
| Q4 25 | $-40.0M | $27.5M | ||
| Q3 25 | $-2.1M | $26.5M | ||
| Q2 25 | $-17.9M | $17.2M | ||
| Q1 25 | — | $20.9M | ||
| Q4 24 | $-11.2M | $3.2M | ||
| Q3 24 | $-31.9M | $7.0M | ||
| Q2 24 | $-38.8M | $752.0K | ||
| Q1 24 | $-24.3M | $8.4M |
毛利率FOSLPAHC
| Q4 25 | 49.0% | 35.5% | ||
| Q3 25 | 57.5% | 32.9% | ||
| Q2 25 | 61.3% | 29.0% | ||
| Q1 25 | — | 30.1% | ||
| Q4 24 | 53.9% | 32.9% | ||
| Q3 24 | 49.4% | 32.1% | ||
| Q2 24 | 52.6% | 31.9% | ||
| Q1 24 | 52.4% | 30.2% |
营业利润率FOSLPAHC
| Q4 25 | -8.0% | 13.5% | ||
| Q3 25 | 3.9% | 14.1% | ||
| Q2 25 | -2.9% | 8.9% | ||
| Q1 25 | — | 9.6% | ||
| Q4 24 | -4.8% | 8.3% | ||
| Q3 24 | -8.5% | 6.8% | ||
| Q2 24 | -13.1% | 6.7% | ||
| Q1 24 | -11.5% | 7.6% |
净利率FOSLPAHC
| Q4 25 | -14.8% | 7.3% | ||
| Q3 25 | -1.0% | 7.3% | ||
| Q2 25 | -7.7% | 4.5% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | -3.3% | 1.0% | ||
| Q3 24 | -11.1% | 2.7% | ||
| Q2 24 | -14.9% | 0.3% | ||
| Q1 24 | -9.5% | 3.2% |
每股收益（稀释后）FOSLPAHC
| Q4 25 | $-0.76 | $0.67 | ||
| Q3 25 | $-0.04 | $0.65 | ||
| Q2 25 | $-0.33 | $0.43 | ||
| Q1 25 | — | $0.51 | ||
| Q4 24 | $-0.15 | $0.08 | ||
| Q3 24 | $-0.60 | $0.17 | ||
| Q2 24 | $-0.73 | $0.02 | ||
| Q1 24 | $-0.46 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $79.2M | $74.5M |
| 总债务越低越好 | $169.1M | $624.2M |
| 股东权益账面价值 | $112.6M | $332.4M |
| 总资产 | $701.0M | $1.4B |
| 负债/权益比越低杠杆越低 | 1.50× | 1.88× |
8季度趋势，按日历期对齐
现金及短期投资FOSLPAHC
| Q4 25 | $79.2M | $74.5M | ||
| Q3 25 | $109.9M | $85.3M | ||
| Q2 25 | $78.3M | $77.0M | ||
| Q1 25 | — | $70.4M | ||
| Q4 24 | $123.6M | $67.1M | ||
| Q3 24 | $106.3M | $89.8M | ||
| Q2 24 | $104.9M | $114.6M | ||
| Q1 24 | $112.9M | $98.7M |
总债务FOSLPAHC
| Q4 25 | $169.1M | $624.2M | ||
| Q3 25 | $165.6M | $628.0M | ||
| Q2 25 | $167.2M | $631.7M | ||
| Q1 25 | — | $635.4M | ||
| Q4 24 | $162.7M | $639.1M | ||
| Q3 24 | $173.4M | $295.2M | ||
| Q2 24 | $156.5M | $312.1M | ||
| Q1 24 | $202.9M | — |
股东权益FOSLPAHC
| Q4 25 | $112.6M | $332.4M | ||
| Q3 25 | $150.3M | $311.7M | ||
| Q2 25 | $140.6M | $285.7M | ||
| Q1 25 | — | $266.0M | ||
| Q4 24 | $148.7M | $246.8M | ||
| Q3 24 | $164.4M | $258.5M | ||
| Q2 24 | $189.6M | $256.6M | ||
| Q1 24 | $229.1M | $270.1M |
总资产FOSLPAHC
| Q4 25 | $701.0M | $1.4B | ||
| Q3 25 | $704.5M | $1.4B | ||
| Q2 25 | $686.0M | $1.4B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | $763.6M | $1.3B | ||
| Q3 24 | $812.4M | $966.3M | ||
| Q2 24 | $785.7M | $982.2M | ||
| Q1 24 | $891.0M | $979.0M |
负债/权益比FOSLPAHC
| Q4 25 | 1.50× | 1.88× | ||
| Q3 25 | 1.10× | 2.01× | ||
| Q2 25 | 1.19× | 2.21× | ||
| Q1 25 | — | 2.39× | ||
| Q4 24 | 1.09× | 2.59× | ||
| Q3 24 | 1.06× | 1.14× | ||
| Q2 24 | 0.83× | 1.22× | ||
| Q1 24 | 0.89× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $19.4M |
| 自由现金流经营现金流 - 资本支出 | $-22.5M | $8.3M |
| 自由现金流率自由现金流/营收 | -8.3% | 2.2% |
| 资本支出强度资本支出/营收 | 0.1% | 3.0% |
| 现金转化率经营现金流/净利润 | — | 0.70× |
| 过去12个月自由现金流最近4个季度 | $-46.0M | $47.3M |
8季度趋势，按日历期对齐
经营现金流FOSLPAHC
| Q4 25 | $-22.2M | $19.4M | ||
| Q3 25 | $9.4M | $9.3M | ||
| Q2 25 | $-60.4M | $21.3M | ||
| Q1 25 | — | $43.2M | ||
| Q4 24 | $30.5M | $3.1M | ||
| Q3 24 | $-22.8M | $12.6M | ||
| Q2 24 | $38.4M | $28.4M | ||
| Q1 24 | $622.0K | $11.4M |
自由现金流FOSLPAHC
| Q4 25 | $-22.5M | $8.3M | ||
| Q3 25 | $8.6M | $-4.5M | ||
| Q2 25 | $-60.6M | $8.1M | ||
| Q1 25 | — | $35.4M | ||
| Q4 24 | $28.5M | $-4.7M | ||
| Q3 24 | $-24.1M | $3.0M | ||
| Q2 24 | $36.6M | $15.4M | ||
| Q1 24 | $-1.1M | $1.7M |
自由现金流率FOSLPAHC
| Q4 25 | -8.3% | 2.2% | ||
| Q3 25 | 3.9% | -1.2% | ||
| Q2 25 | -26.0% | 2.1% | ||
| Q1 25 | — | 10.2% | ||
| Q4 24 | 8.3% | -1.5% | ||
| Q3 24 | -8.4% | 1.2% | ||
| Q2 24 | 14.1% | 5.6% | ||
| Q1 24 | -0.4% | 0.6% |
资本支出强度FOSLPAHC
| Q4 25 | 0.1% | 3.0% | ||
| Q3 25 | 0.4% | 3.8% | ||
| Q2 25 | 0.1% | 3.5% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | 0.6% | 2.5% | ||
| Q3 24 | 0.4% | 3.7% | ||
| Q2 24 | 0.7% | 4.8% | ||
| Q1 24 | 0.7% | 3.7% |
现金转化率FOSLPAHC
| Q4 25 | — | 0.70× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 2.07× | ||
| Q4 24 | — | 0.97× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | — | 37.80× | ||
| Q1 24 | — | 1.36× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FOSL
| Transferred At Point In Time | $109.7M | 41% |
| Traditional Watches | $91.3M | 34% |
| Other | $50.8M | 19% |
| Leathers | $9.5M | 4% |
| Jewelry | $4.0M | 1% |
| Smartwatches | $3.3M | 1% |
| Products Other | $1.6M | 1% |
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
